Development · 17 Sep 2026
AUROPHARMA, full dossier5 publishers have reported this development. Each act of reporting is below, cited.
Aurobindo Pharma announced that it has received final approval to manufacture and market beclomethasone dipropionate hfa inhalation aerosol in the US.
Aurobindo Pharma announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg.
Aurobindo Pharma has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol.
Aurobindo Pharma has received final approval from the US Food and Drug Administration to manufacture and market its first metered-dose inhaler for asthma treatment in the United States.
2 Oct 2026 · 1 publisher
2 Oct 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.